Filing Flows › IGC Pharma (IGC) › Who owns the stock
Who owns IGC Pharma (IGC) stock
42 funds reported IGC Pharma (IGC) shares in their latest 13F filings, worth $1.8M in all. The largest holder is Vanguard Group ($323K). Last quarter 14 funds added to their stakes and 11 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| Vanguard Group | 1,149,268 | $323K | unchanged | 2025-12-31 |
| Geode Capital Management, LLC | 879,394 | $239K | decrease | 2026-06-30 |
| Vanguard Capital Management LLC | 814,914 | $222K | increase | 2026-06-30 |
| BlackRock | 703,798 | $191K | unchanged | 2026-06-30 |
| AdvisorShares Investments LLC | 678,480 | $185K | new | 2026-06-30 |
| Citadel Advisors LLC | 437,317 | $119K | new | 2026-06-30 |
| Vanguard Fiduciary Trust | 419,413 | $114K | increase | 2026-06-30 |
| Renaissance Technologies LLC | 286,608 | $78K | decrease | 2026-06-30 |
| State Street | 200,799 | $55K | unchanged | 2026-06-30 |
| Northern Trust | 170,274 | $46K | increase | 2026-06-30 |
| Dearborn Partners LLC | 118,802 | $32K | increase | 2026-06-30 |
| Lawood | 75,000 | $20K | unchanged | 2026-09-30 |
| Goldman Sachs Group | 65,541 | $18K | unchanged | 2026-06-30 |
| Jane Street Group, LLC | 62,610 | $17K | new | 2026-06-30 |
| Truist Financial | 48,667 | $13K | increase | 2026-06-30 |
IGC Pharma's latest quarter
IGC Pharma, Q3 2026: revenue $328K (+72% year over year), operating margin -588.7%, net loss $2.0M, operating cash flow −$1.4M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most IGC stock?
By the latest 13F filings: Vanguard Group ($323K); Geode Capital Management, LLC ($239K); Vanguard Capital Management LLC ($222K); BlackRock ($191K); AdvisorShares Investments LLC ($185K).
What is the short interest in IGC?
635,640 shares were sold short at the 2026-10-15 settlement, -31.76% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.